| Literature DB >> 16102655 |
Tuomas Jartti1, Mika J Mäkelä, Timo Vanto, Olli Ruuskanen.
Abstract
Bronchiolitis and asthma are common wheezing illnesses of childhood. Respiratory syncytial virus is the main causative agent of Bronchiolitis. Rhinovirus is the most common trigger of exacerbations of asthma, but also has been detected increasingly in doing children with Bronchiolitis. Reportedly, childhood asthma develops in 40% of children with a history of Bronchiolitis. No convincing link has been reported between Bronchiolitis and development of atopy, although atopy generally is regarded as the main risk factor for chronic asthma. This article focuses on the association between bronchiolitis and the development of asthma. The authors address the question how respiratory syncytial virus and rhinovirus infections in young children, together with genetics and immunologic immaturity, may contribute to the development of asthma.Entities:
Mesh:
Year: 2005 PMID: 16102655 PMCID: PMC7118846 DOI: 10.1016/j.idc.2005.05.010
Source DB: PubMed Journal: Infect Dis Clin North Am ISSN: 0891-5520 Impact factor: 5.982
Fig. 1Multifactorial influences on the development of asthma. BHR, bronchial hyperreactivity. (From Openshaw PJ, Yamaguchi Y, Tregoning JS. Childhood infections, the developing immune system, and the origins of asthma. J Allergy Clin Immunol 2004;114:1276; with permission.)
Studies on viral etiology of bronchiolitis
| Wheezing episodes/control subjects | Viral identification rates (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year of study | Age (mo) | RSV | Rhinovirus | Enteroviruses | Parainfluenza virus | Influenza virus | Adenovirus | Coronavirus | hMPV | Total positive | |
| 1999 | 22/17 | <24 | 68/0 | 41/41 | 1/0 | 0/1 | 0/1 | 82 | |||
| 2000 | 84 | <12 | 54 | 19 | 12 | 0 | 0 | 13 | 0 | 74 | |
| 2002 | 118 | <18 | 53 | 21 | 3 | 3 | 8 | 3 | 74 | ||
| 2003 | 81 | <24 | 26 | 33 | 12 | 14 | 5 | 0 | 73 | ||
| 2004 | 71 | 3–12 | 55 | 18 | 14 | 6 | 3 | 1 | 1 | 11 | 90 |
| 179/17 | 3–36 | 36 | 21/0 | 21/0 | 5 | 2 | 5 | 2 | 7 | 87 | |
Abbreviations: hMPV, human metapneumovirus; RSV, respiratory syncytial virus.
Including studies using polymerase chain reaction with a sampling period of >1 year.
With polymerase chain reaction; 23/25 using culture only.
New subgroup analysis.
Nontypable rhino-enterovirus: 15/18.
Studies on viral etiology of acute asthma
| Wheezing episodes/control subjects | Viral identification rates (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year of study | Age (y) | RSV | Rhinovirus | Enteroviruses | Parainfluenza virus | Influenza A/B virus | Adenovirus | Coronavirus | hMPV | Total positive | |
| 1995 | 161 | 9–11 | 4 | 50 | 7 | 7 | 13 | 80 | |||
| 1999 | 48/42 | 2–16 | 6/0 | 71/36 | 2/0 | 2/0 | 2/0 | 6/0 | 83 | ||
| 1999 | 71 | ≤2 | 24 | 44 | 10 | 4 | 10 | 5 | 5 | 86 | |
| 61 | >2 | 18 | 51 | 77 | |||||||
| 2003 | 179 | 0.1–17 | 7 | 79 | 1 | 2 | 2 | 88 | |||
| 2004 | 49/17 | 0.4–3 | 22 | 27/0 | 33/0 | 4 | 4 | 12 | 0 | 0 | 90 |
| 65/25 | 3–16 | 8 | 31/0 | 38/0 | 9 | 2 | 2 | 2 | 0 | 91 | |
Abbreviations: hMPV, human metapneumovirus; RSV, respiratory syncytial virus.
Including studies using polymerase chain reaction with a sampling period of >1 year.
Number is for picornaviruses, of which 57% were rhinoviruses, the remaining viruses could not be cultured and were classified as rhinoviruses because most enteroviruses culture easily.
In reported falls in peak expiratory flow.
Children with wheezing were included. Excluded were children with bronchopulmonary dysplasia or using corticosteroids within the previous week.
With polymerase chain reaction; 18/24% using culture only.
Information not available of different age groups.
New subgroup analyses.
Nontypable rhino-enterovirus: 12/18 in children age <3 y and 17/12 in children age ≥3 y.
Important long-term studies of the link between bronchiolitis and reactive airway disease
| No. patients/controls | Viral etiology (%) | End points and results: patients versus controls (odds ratio, 95% CI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| First author | Year | Design | Age on entry (mo) | RSV | Other | Follow-up time (y) | Recurrent wheezing | Physician-diagnosed asthma | Abnormal pulmonary function test | Atopy | |
| Sims | 1978 | Ret | 35/35 | <12 | 100 | 8 | 51% vs 3% ( | PEF 237 L/mm vs 265 L/min ( | NS | ||
| Pullan | 1982 | Ret | 130/111 | <12 (mean 4) | 100 | 10 | 42% vs 19% ( | NS | Exercise test or histamine challenge positive 25% vs 7% ( | NS | |
| Mok | 1982 | Ret | 200/200 | <12 (mean 4) | 50 | 7 | 47% vs 17% ( | 9% vs 2.5% ( | FEV1 91% vs 95% predicted ( | ||
| McConnochie | 1984 | Ret | 59/177 | <24 | 8 | 44% vs 14% ( | 25% vs 7% ( | ||||
| McConnochie | 1985 | Ret | 25/25 | <24 | 8–12 | FEF25–75 baseline 64% vs 75% predicted ( | |||||
| McConnochie | 1989 | Ret | 51/102 | <24 | 13 | NS | NS | ||||
| Carlsen | 1987 | Pro | 51/24 | <1 | 61 | 6 | 2 | No. episodes, median 3 vs 0 ( | NS | ||
| Osundwa | 1993 | Ret | 70/70 | Mean 4 (range 3–8) | 100 | 2 | 44% vs 12.9% ( | ||||
| Noble | 1997 | Pro | 61/47 | Mean 4 (range 1–12) | 66 | 9–10 | 34% vs 13% (3.6, 1.3–9.8, | 39% vs 13% (4.4, 1.6–12, | Baseline PEF 93% vs 102% predicted (95% CI of differences 4.1–13.4, | NS | |
| Stein | 1999 | Pro | 68/669 | <36 | 44 | 28 | 6 | Year 11: RSV 2.4, 1.3–4.6, | Year 11: RSV FEV1 baseline 2.1, 2.1–2.2, | NS | |
| 56/545 | 8 | ||||||||||
| 79/634 | 11 | ||||||||||
| 49/469 | 13 | ||||||||||
| Weber | 1999 | Pro | 105/105 | Median 4 (quartiles 2–6) | 3 | 10% vs 1% | |||||
| Kneyber | 2000 | Meta-analysis | 117/163 | <12 | 0–100 | <5 | <5 y: 36% vs 6% (5.5, 2.4–12.6) | NS | |||
| 230/321 | <12 | ≥5 | |||||||||
| Kotaniemi-Syrjänen | 2003 | Pro | 44 | 1–24 | 23 | 45 | 6 | 4.1, 1–16.8 ( | NS | ||
| Sigurs | 2000 | Pro | 47/93 | <12 (mean 4) | 100 | 7 | Year 7: 68% vs 34% ( | Year 13: 37% vs 5.4% ( | Year 13: baseline FEV1/FVC 85% vs 88% predicted ( | Year 7: 41% vs 22% ( | |
| 2004 | 13 | ||||||||||
| Piippo-Savolainen | 2004 | Pro | 54/45 | Median 10 (range 1–24) | 19 | 30% vs 11% (3.4, 1.1–10.1) | Abnormal pulmonary function 36% vs 11% (4.5, 1.5–13.2) | NS | |||
Abbreviations: FEF25–75, forced expiratory flow at 25–75% range; FEV1, forced expiratory flow in 1 second; IRR, incidence rate ratio; NS, nonsignificant; PEF, peak expiratory flow; Pro, prospective; Ret, retrospective; RSV, respiratory syncytial virus.
Only the last positive reports are included of studies with many interim analyses.
Confirmed by specific IgE antibodies or skin prick test.
Inclusion criteria.
Cumulative.
Currently or previous year.
Parainfluenza n = 2 (4%), rhinovirus n = 1 (2%).
Parainfluenza n = 68 (14%), other viruses n = 68 (14%) (including adenovirus, influenza virus, cytomegalovirus, rhinovirus, bacterial and mixed infections), negative test n = 129 (27%).
Including [75], [76], [79], [86].
Rhinovirus n = 20 and virus negative n = 14.
Between rhinovirus-positive and rhinovirus-negative cases.
For any test positive.
Comparison included pneumonia group, which is not shown.